Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Welcome to the latest edition of touchREVIEWS in Infectious Diseases, where we continue our mission to deliver insightful, cutting-edge perspectives in infectious disease diagnosis and management. This issue offers an array of topics spanning diagnostics, service delivery innovations and preventive care, reflecting the dynamic challenges and opportunities in our field. In our first editorial, Barbara […]

David Lawrence, IAS 2021: Liposomal Amphotericin B Deoxycholate for the treatment of HIV-associated Cryptococcal Meningitis

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Aug 17th 2021

We had the pleasure to meet with David Lawrence (London School of Hygiene and Tropical Medicine, London, UK) to discuss single high-dose liposomal amphotericin based regimen for treatment of HIV-associated Cryptococcal Meningitis.

The abstract entitled: ‘Single high-dose liposomal amphotericin based regimen for treatment of HIV-associated Cryptococcal Meningitis: results of the phase-3 Ambition-cm Randomised Trial’ was presented at IAS 2021 – the 11th International AIDS Society Conference on HIV Science (Virtual).

Questions:

  1. Could you tell us a little about HIV-associated cryptococcal meningitis (CM), and its health burden in sub-Saharan Africa? (0:20)
  2. What treatment options are recommended for CM and what are their limitations? (0:41)
  3. What is the rationale for the use of a single, high-dose of liposomal amphotericin B deoxycholate in this treatment setting? (2:08)

Disclosures: David Lawrence has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed in coverage of IAS 2021 Virtual.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup